Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Baxter’s Heparin Ingredients Supplied By Unlicensed Chinese Company

This article was originally published in PharmAsia News

Executive Summary

The active pharmaceutical ingredient in Baxter Internationals' blood thinner Heparin (heparin sodium) came from a factory in Changzhou, China, that had not been certified by China's State FDA. As a result, neither Chinese nor U.S. authorities had inspected the Changzhou Scientific Protein Laboratories plant where the API was made from pig intestines. The cause of four deaths and complications reported by 350 patients has not been determined. A Baxter spokeswoman said her company had inspected the plant on its own volition less than six months ago, but the U.S. supplier acknowledged the Changzhou plant had not been licensed by the SFDA. Scientific Protein did say the raw materials used had come from a licensed plant. (Click here for more

You may also be interested in...



Chinese Heparin API Manufacturer Not Inspected By SFDA

SHANGHAI - China's State FDA has never inspected an API manufacturer that may be linked to a safety scare over Baxter Healthcare's injectable heparin, officials confirmed to PharmAsia News

QUOTED. 22 October. Robert Ford.

Abbott reported third-quarter 2020 global sales of $8.9bn, driven by its strong position in COVID-19 tests. See what Abbott’s CEO Robert Ford said about it here.

China Regulatory Express: Biosecurity Law, Export Controls And The Life Science Sector

With the threat of potentially hefty fines, China's newly passed Biosecurity Law will fundamentally change how the life science sector handles human genetic resources over years to come, legal experts say.

UsernamePublicRestriction

Register

OM003387

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel